PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT RIFAMPICIN SINGLE DOSES: RELEVANCE OF FIRST-PASS EFFECT FROM HEPATIC UPTAKE TRANSPORTERS, AND INTESTINAL AND HEPATIC METABOLISM

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Drug Metabolism And Disposition

• Publication date

  2006-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/dmd.105.009076PMID 16624870
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems

  2006influential reference
• Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.

  2005cited by this paper
• Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells

  2005cited by this paper
• DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1

  2005cited by this paper
• Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System

  2004cited by this paper
• CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and Midazolam

  2004influential reference
• Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter Interplay

  2004cited by this paper
• Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin

  2004cited by this paper
• Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes.

  2004cited by this paper
• Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918.

  2003cited by this paper
• Clinical Pharmacokinetics of Atorvastatin

  2003cited by this paper
• Comparative Inhibitory Effects of Different Compounds on Rat Oatp1 (Slc21a1)- and Oatp2 (Slc21a5)-Mediated Transport

  2002influential reference
• Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.

  2002cited by this paper
• The impact of P‐glycoprotein efflux on enterocyte residence time and enterocyte‐based metabolism of verapamil

  2001cited by this paper
• Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans.

  2001influential reference
• Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter

  2000cited by this paper
• The effect of rifampin treatment on intestinal expression of human MRP transporters.

  2000cited by this paper
• Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2

  2000influential reference
• Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.

  2000cited by this paper
• A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)

  1999cited by this paper
• Metabolism and excretion of atorvastatin in rats and dogs.

  1999cited by this paper
• Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.

  1999cited by this paper
• Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations

  1999cited by this paper
• Effect of itraconazole on the pharmacokinetics of atorvastatin

  1998cited by this paper
• Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

  1998cited by this paper
• Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine.

  1998cited by this paper
• Absolute bioavailability of atorvastatin im man

  1997cited by this paper
• P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.

  1996cited by this paper
• Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine

  1995influential reference
• The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine

  1995cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993influential reference
• Plasma and tissue binding considerations in drug disposition.

  1983cited by this paper
• Noncompartmental determination of the steady-state volume of distribution.

  1979cited by this paper

• Impact of OATP2B1 on Pharmacokinetics of Atorvastatin Investigated in rSlco2b1-Knockout and SLCO2B1-Knockin Rats

  2024cites this paper
• Intestinal Lymphatic Biology, Drug Delivery, and Therapeutics: Current Status and Future Directions

  2024cites this paper
• Rat PermQ: A permeability- and perfusion-based physiologically based pharmacokinetic model for improved prediction of drug concentration-time profiles in rat.

  2024cites this paper
• Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats

  2023cites this paper
• Development and Characterization of Pentaerythritol-EudragitRS100 Co-processed Excipients as Solid Dispersion Carriers for Enhanced Aqueous Solubility, In Vitro Dissolution, and Ex Vivo Permeation of Atorvastatin

  2023cites this paper
• Management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms

  2023cites this paper
• Design and synthesis of atorvastatin derivatives with enhanced water solubility, hepatoselectivity and stability.

  2023cites this paper
• A Study on Pharmacokinetic Functionalities and Safety Margins of an Optimized Simvastatin Nanoformulation

  2023cites this paper
• Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human

  2022influential citation
• Potential Involvement of Organic Anion Transporters in Drug Interactions with Shuganning Injection, a Traditional Chinese Patent Medicine

  2022cites this paper
• Comparative Hepatic and Intestinal Efflux Transport of Statins

  2021cites this paper
• The utility of endogenous glycochenodeoxycholate-3-sulfate and 4β-hydroxycholesterol to evaluate the hepatic disposition of atorvastatin in rats

  2021cites this paper
• Global Analysis of Models for Predicting Human Absorption: QSAR, In Vitro, and Preclinical Models.

  2021cites this paper
• Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study

  2021cites this paper
• Statins mediate anti- and pro-tumourigenic functions by remodelling the tumour microenvironment

  2021cites this paper
• Development, optimization, and in vitro evaluation of atorvastatin calcium and vinpocetine codelivery by solid lipid nanoparticles for cancer therapy

  2021cites this paper
• Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins

  2021cites this paper
• The potential of Atorvastatin for chronic lung diseases therapy

  2020cites this paper
• A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats

  2020influential citation
• Solubility enhancement of atorvastatin by embedding in micro sized carrier

  2019cites this paper
• Synergistic and protective effect of atorvastatin and amygdalin against histopathological and biochemical alterations in Sprague-Dawley rats with experimental endometriosis

  2019cites this paper
• Development and Permeability Testing of Self-Emulsifying Atorvastatin Calcium Pellets and Tablets of Compressed Pellets

  2019cites this paper
• Modulation of transporter activity of OATP1B1 and OATP1B3 by the major active components of Radix Ophiopogonis

  2019cites this paper
• Influence of Preparation Methods on Physicochemical and Pharmacokinetic Properties of Co-amorphous Formulations: The Case of Co-amorphous Atorvastatin: Naringin

  2019cites this paper
• Organic Anion–Transporting Polypeptide (OATP)–Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver

  2018cites this paper
• Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats

  2018cites this paper
• Inhibition of Organic Anion Transporting Polypeptide 1B1 and 1B3 by Betulinic Acid: Effects of Preincubation and Albumin in the Media.

  2018cites this paper
• Organic Cation Transporter 1 Is Responsible for Hepatocellular Uptake of the Tyrosine Kinase Inhibitor Pazopanib

  2018cites this paper
• Simultaneous Assessment In Vitro of Transporter and Metabolic Processes in Hepatic Drug Clearance: Use of a Media Loss Approach

  2018cites this paper
• Microwave Generated Nanocomposites for Solubility Enhancement of Atorvastatin Calcium: In Vitro- In Vivo Characterization

  2018cites this paper
• Clearance Prediction Methodology Needs Fundamental Improvement: Trends Common to Rat and Human Hepatocytes/Microsomes and Implications for Experimental Methodology

  2017cites this paper
• Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: Ameliorated effect without liver toxicity in poloxamer 407‐induced hyperlipidemic rats

  2017cites this paper
• High-Dose Metformin May Increase the Concentration of Atorvastatin in the Liver by Inhibition of Multidrug Resistance-Associated Protein 2.

  2017cites this paper
• Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks

  2017cites this paper
• Human biliary amount prediction using simple, bile flow-rate corrected and uridine diphosphate glucuronosyltransferase activity corrected allometric methods

  2017cites this paper
• Organic anion transporting polypeptides (OATPs)-mediated drug-drug interaction study between rosuvastatin and cyclosporine A in chimeric mice with humanized liver

  2017cites this paper
• Conductometric and volumetric studies of atorvastatin in aqueous solution of arginine from 298.15 to 313.15 K

  2016cites this paper
• Application of Organ Clearance to Estimation of the In Vivo Hepatic Extraction Ratio.

  2016cites this paper
• Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat

  2016cites this paper
• Development and Validation of a Discriminating Dissolution Method for Atorvastatin Delayed-Release Nanoparticles Using a Flow-Through Cell: A Comparative Study Using USP Apparatus 4 and 1

  2016cites this paper
• Artificial Neural Networks in Drug Transport Modeling and Simulation–I

  2016cites this paper
• Atorvastatin up-regulates the expression and activity of renal Cytochrome P450 3A2 in diabetic rats

  2016cites this paper
• Clinical Effectiveness of Subgingivally Delivered Rosuvastatin in Comparison with Atorvastatin in the Treatment of Chronic Periodontitis

  2016cites this paper
• Factors that Impact the Developability of Drug Candidates

  2016cites this paper
• Increased intestinal P-glycoprotein expression and activity with progression of diabetes and its modulation by epigallocatechin-3-gallate: Evidence from pharmacokinetic studies.

  2015cites this paper
• Preparation, in‐vitro and in‐vivo evaluation of spray‐dried ternary solid dispersion of biopharmaceutics classification system class II model drug

  2015cites this paper
• Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy

  2015cites this paper
• Preparation and characterization of Simvastatin solid dispersion using skimmed milk

  2015cites this paper
• Effects of carbohydrate polymers in self-microemulsified tablets on the bioavailability of atorvastatin: In vitro-in vivo study.

  2015cites this paper
• Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir

  2015cites this paper
• Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin

  2015cites this paper
• Interplay of Drug-Metabolizing Enzymes and Transporters in Drug Absorption and Disposition.

  2014cites this paper
• Low-dose combination of alendronate and atorvastatin reduces ligature-induced alveolar bone loss in rats.

  2014cites this paper
• Differential Effects of Rifampin and Ketoconazole on the Blood and Liver Concentration of Atorvastatin in Wild-Type and Cyp3a and Oatp1a/b Knockout Mice

  2014influential citation
• Effect of Atorvastatin on Pharmacology of Sitagliptin in Streptozotocin-Nicotinamide Induced Type-II Diabetes in Rats

  2014cites this paper
• Practical permeability-based hepatic clearance classification system (HepCCS) in drug discovery.

  2014cites this paper
• Transport characteristics and transporter‐based drug–drug interactions of TM‐25659, a novel TAZ modulator

  2014cites this paper
• Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats

  2014cites this paper
• Interplay of drug metabolizing enzymes with cellular transporters

  2014cites this paper
• In Vitro Dissoluion Study to Determine Drug – Drug Interaction of Atorvastatin Calcium

  2014cites this paper
• Concomitant Use of Carbamazepine and Rifampin in a Patient With Mycobacterium avium Complex and Seizure Disorder

  2014cites this paper
• Mechanistic prediction of intestinal first-pass metabolism using in vitro data in preclinical species and in man

  2014influential citation
• Role of Organic Anion Transporting Polypeptides (OATPs) in the cellular accumulation of antitumor agents in lung, breast and liver cancer

  2014cites this paper
• DRUG-DRUG INTERACTION OF DHP AND OTHER LIPID LOWERING DRUG

  2014cites this paper
• Contribution of rat intestinal metabolism to the xenobiotics clearance

  2013cites this paper
• Microsoft Word-42761122-file00.docx

  2013cites this paper
• Integrated Approach of In Vivo and In Vitro Evaluation of the Involvement of Hepatic Uptake Organic Anion Transporters in the Drug Disposition in Rats Using Rifampicin as an Inhibitor

  2013cites this paper
• The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.

  2013cites this paper
• ATP-dependent transport of statins by human and rat MRP2/Mrp2.

  2013cites this paper
• Dissolution Improvement of Atorvastatin Calcium using Modified Locust Bean Gum by the Solid Dispersion Technique

  2013cites this paper
• Effects of Selected OATP and/or ABC Transporter Inhibitors on the Brain and Whole-Body Distribution of Glyburide

  2013cites this paper
• Combined Analysis of Pharmacokinetic and Efficacy Data of Preclinical Studies with Statins Markedly Improves Translation of Drug Efficacy to Human Trials

  2013cites this paper
• Utility of In Vitro Systems and Preclinical Data for the Prediction of Human Intestinal First-Pass Metabolism during Drug Discovery and Preclinical Development

  2013cites this paper
• Integrated Approach of In Vivo and In Vitro Evaluation of the Involvement of Hepatic Uptake Organic Anion Transporters in the Drug Disposition in Rats Using Rifampicin as an Inhibitor

  2013cites this paper
• Hypothesis Generation and Pharmacokinetic Predictions

  2012cites this paper
• Quantitative intravital microscopy of hepatic transport

  2012cites this paper
• Drug–drug interaction study to assess the effects of atorvastatin co‐administration on pharmacokinetics and anti‐thrombotic properties of cilostazol in male Wistar rats

  2012cites this paper
• Influence of Rifampicin on the Pharmacokinetics of Salvianolic Acid B May Involve Inhibition of Organic Anion Transporting Polypeptide (Oatp) Mediated Influx

  2012cites this paper
• The Role of Drug Transporters in Statin-Induced Myopathy

  2012cites this paper
• In Silico Models of Drug Metabolism and Drug Interactions

  2012cites this paper
• Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability

  2012cites this paper
• Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats

  2012cites this paper
• Saturable sinusoidal uptake is rate-determining process in hepatic elimination of docetaxel in rats

  2012influential citation
• Influence of atorvastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits

  2012cites this paper
• Novel In Vitro-In Vivo Extrapolation (IVIVE) Method to Predict Hepatic Organ Clearance in Rat

  2012cites this paper
• Increased toxicity when fibrates and statins are administered in combination--a metabolomics approach with rats.

  2012cites this paper
• Organic anion transporter 1B1 (SLCO1B1) polymorphism and gallstone formation: High incidence of Exon4 CA genotype in female patients in North India

  2011cites this paper
• Patients' report of statins use and side-effects in a sample of hospitalized cardiac patients in the Islamic Republic of Iran.

  2011cites this paper
• BDDCS Applied to Over 900 Drugs

  2011cites this paper
• Differential effects of atorvastatin treatment and withdrawal on pentylenetetrazol‐induced seizures

  2011cites this paper
• Pharmacokinetics and Hepatic Uptake of Eltrombopag, a Novel Platelet-Increasing Agent

  2011cites this paper
• PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism.

  2010cites this paper
• Clearance (née Rowland) concepts: a downdate and an update

  2010cites this paper
• Solid State Characterization of Commercial Crystalline and Amorphous Atorvastatin Calcium Samples

  2010cites this paper
• Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System.

  2010cites this paper
• Regulation of the Inducible L-Arginine-Nitric Oxide Pathway by Oxidative Stress and Statins

  2010cites this paper
• Factors Affecting the In Vivo Lactone Stability and Systemic Clearance of the Lipophilic Camptothecin Analogue AR-67

  2010cites this paper
• Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin

  2010cites this paper
• Clearance (née Rowland) a downdate and an update.

  2010cites this paper
• Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy Subjects

  2010cites this paper